Lawsuits · Federal Circuit
Federal Circuit Dismisses Sarepta's IPR Appeal Against Penn and REGENXBIO by Agreement
A nonprecedential October 8 order dismissed Sarepta Therapeutics' appeal from the Patent Trial and Appeal Board in IPR2024-00580 under Federal Rule of Appellate Procedure 42(b), with each side bearing its own costs.
By Michael P. Eddy · October 12, 2026 · 1 min read
The case is Sarepta Therapeutics, Inc. v. Trustees of the University of Pennsylvania, No. 2026-1071, with REGENXBIO Inc. also named as an appellee. Sarepta was the appellant in an appeal from the Patent Trial and Appeal Board in IPR2024-00580 (Order 1).
The order begins "The parties having so agreed" and directs that the proceeding be dismissed under Federal Rule of Appellate Procedure 42(b) and that "[e]ach side shall bear their own costs" (Order 1). It is dated October 8, 2026, and was issued as the mandate the same day (Order 2). The court marked it nonprecedential.
The order does not name the patent at issue, describe the Board's decision, or state the terms of any agreement between the parties.
Attorney advertising. Patent.org is published by the Law Office of Michael P. Eddy. Commentary is based on public records and other public sources, is general information rather than legal advice, and reading it does not create an attorney-client relationship. Nothing here guarantees or predicts the outcome of any particular matter.